Physician profile
Mark L Dillingham
NPI 1568495448
$799.59
in general payments reported to CMS, 2019-2025
17 companies · $72.64 in 2025
The $72.64 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.10 · 2022: $85.25 · 2023: $358 · 2024: $251 · 2025: $72.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $144.26 | 2023-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $112.56 | 2021-2024 | Ingrezza |
| Novo Nordisk INC | $74.68 | 2022-2025 | Rybelsus, Ozempic |
| Myriad Women'S Health, INC. | $69.31 | 2023 | Myrisk |
| Abbvie INC. | $57.30 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $48.07 | 2023-2024 | Breztri, Airsupra |
| Pfizer INC. | $46.56 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $45.26 | 2023-2025 | Steglatro, Gardasil 9, Rotateq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.89 | 2023-2024 | Caplyta |
| Glaxosmithkline, LLC. | $30.61 | 2023 | Trelegy Ellipta |
| Organon LLC | $30.53 | 2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $20.09 | 2023 | Rexulti |
| Lilly USA, LLC | $19.80 | 2024 | Zepbound, Mounjaro |
| Ironshore Pharmaceuticals INC. | $19.25 | 2022 | |
| Aimmune Therapeutics, INC. | $17.84 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.28 | 2024 | |
| Eisai INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dillingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.